These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 22841680)

  • 1. Dengue virus infection-enhancing and neutralizing antibody balance in children of the Philippines and Indonesia.
    Yamanaka A; Tabuchi Y; Mulyatno KC; Susilowati H; Hendrianto E; Soegijanto S; Konishi E
    Microbes Infect; 2012 Nov; 14(13):1152-9. PubMed ID: 22841680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement-independent dengue virus type 1 infection-enhancing antibody reduces complement-dependent and -independent neutralizing antibody activity.
    Yamanaka A; Konishi E
    Vaccine; 2016 Dec; 34(51):6449-6457. PubMed ID: 27866774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dengue-Immune Humans Have Higher Levels of Complement-Independent Enhancing Antibody than Complement-Dependent Neutralizing Antibody.
    Yamanaka A; Konishi E
    Jpn J Infect Dis; 2017 Sep; 70(5):579-581. PubMed ID: 28367878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Balance of infection-enhancing and neutralizing antibodies induced by a dengue tetravalent DNA vaccine in a mouse model.
    Konishi E; Miyagawa Y
    Microbes Infect; 2011 Nov; 13(12-13):1091-8. PubMed ID: 21763777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of Monoclonal Antibodies against Dengue Virus Type 4 and Identification of Enhancing Epitopes on Envelope Protein.
    Tang CT; Liao MY; Chiu CY; Shen WF; Chiu CY; Cheng PC; Chang GJ; Wu HC
    PLoS One; 2015; 10(8):e0136328. PubMed ID: 26309127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dengue virus infection-enhancing activity of undiluted sera obtained from patients with secondary dengue virus infection.
    Moi ML; Takasaki T; Saijo M; Kurane I
    Trans R Soc Trop Med Hyg; 2013 Jan; 107(1):51-8. PubMed ID: 23296697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dengue virus infection-enhancing antibody activities against Indonesian strains in inhabitants of central Thailand.
    Yamanaka A; Oddgun D; Chantawat N; Okabayashi T; Ramasoota P; Churrotin S; Kotaki T; Kameoka M; Soegijanto S; Konishi E
    Microbes Infect; 2016 Apr; 18(4):277-84. PubMed ID: 26645957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of enhancing-activity-free neutralizing antibody against dengue type 1 virus in plasmid-inoculated mice.
    Yamanaka A; Pitaksajjakul P; Ramasoota P; Konishi E
    Vaccine; 2015 Nov; 33(45):6070-7. PubMed ID: 26259543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes.
    Andrade DV; Katzelnick LC; Widman DG; Balmaseda A; de Silva AM; Baric RS; Harris E
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of infection-neutralizing and -enhancing antibody balance induced by two distinct genotype strains of dengue virus type 1 or 3 DNA vaccines in mice.
    Sjatha F; Takizawa Y; Kotaki T; Yamanaka A; Konishi E
    Microbes Infect; 2013 Nov; 15(12):828-36. PubMed ID: 23911844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of pre-existing cross-reactive antibodies on cyclic dengue outbreaks in the hyperendemic region of Bali, Indonesia.
    Balingit JC; Denis D; Suzuki R; Hayati RF; Ngwe Tun MM; Takamatsu Y; Masyeni S; Sasmono RT; Morita K
    Virus Res; 2024 Oct; 348():199445. PubMed ID: 39089369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of single-round infectious, chimeric dengue type 1 virus as an antigen for dengue functional antibody assays.
    Yamanaka A; Suzuki R; Konishi E
    Vaccine; 2014 Jul; 32(34):4289-95. PubMed ID: 24950360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infection-enhancing and -neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels.
    Yamanaka A; Kosugi S; Konishi E
    J Virol; 2008 Jan; 82(2):927-37. PubMed ID: 18003724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mouse monoclonal antibody against dengue virus type 1 Mochizuki strain targeting envelope protein domain II and displaying strongly neutralizing but not enhancing activity.
    Yamanaka A; Kotaki T; Konishi E
    J Virol; 2013 Dec; 87(23):12828-37. PubMed ID: 24049185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
    Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
    Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model.
    Libraty DH; Acosta LP; Tallo V; Segubre-Mercado E; Bautista A; Potts JA; Jarman RG; Yoon IK; Gibbons RV; Brion JD; Capeding RZ
    PLoS Med; 2009 Oct; 6(10):e1000171. PubMed ID: 19859541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High frequency of pre-existing neutralizing antibody responses in patients with dengue during an outbreak in Central Brazil.
    de Teive E Argolo AF; de Rezende Féres VC; Cordeiro MT; da Silveira LA; Guilarde AO; de Azevedo Marques ET; de Souza WV; Martelli CM
    BMC Infect Dis; 2016 Oct; 16(1):546. PubMed ID: 27717314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of chimeric DNA vaccines consisting of premembrane and envelope genes of Japanese encephalitis and dengue viruses as a strategy for reducing induction of dengue virus infection-enhancing antibody response.
    Sjatha F; Kuwahara M; Sudiro TM; Kameoka M; Konishi E
    Microbiol Immunol; 2014 Feb; 58(2):126-34. PubMed ID: 24372832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody avidity following secondary dengue virus type 2 infection across a range of disease severity.
    Lau L; Green AM; Balmaseda A; Harris E
    J Clin Virol; 2015 Aug; 69():63-7. PubMed ID: 26209381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A simple assay system for infection-enhancing and -neutralizing antibodies to dengue type 2 virus using layers of semi-adherent K562 cells.
    Konishi E; Tabuchi Y; Yamanaka A
    J Virol Methods; 2010 Feb; 163(2):360-7. PubMed ID: 19883692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.